sniklaas schreef op 4 mei 2021 13:48:
@PFE, mooie cijfers, 45% meer omzet maar verwacht niet genoeg om vandaag 10%+ te stijden dus ik laat mijn extra stukken op een lager niveau gaan, ergens rond de $42 moet kunnen vandaag;
s21.q4cdn.com/317678438/files/doc_fin...
PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
? First-Quarter 2021 Revenues of $14.6 Billion, Reflecting 42% Operational Growth; Excluding Revenues for
BNT162b2 of $3.5 Billion, Revenues Grew 8% Operationally Including a Negative 5% Impact from Pricing
? First-Quarter 2021 Reported Diluted EPS(1) of $0.86, Adjusted Diluted EPS(2) of $0.93
? Raises Full-Year 2021 Guidance(3) for Revenues to a Range of $70.5 to $72.5 Billion and Adjusted Diluted
EPS(2) to a Range of $3.55 to $3.65, Primarily Reflecting Updates to Anticipated Contributions from
BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well
as Other mRNA-Based Development Programs and COVID-19 Antivirals
– Now Anticipates Revenues of Approximately $26 Billion for BNT162b2, Reflecting 1.6 Billion Doses
Expected to be Delivered in 2021 Under Signed Contracts as of Mid-April 2021
– Raises Revenue Guidance Range Excluding BNT162b2 by $200 Million, Reflecting Continued Strong
Performance of the Business
? Enters Into Contracts to Supply BNT162b2 to Canada and Israel for Periods Beyond 2021; Currently
Negotiating Similar Potential Contracts with Multiple Other Countries
? Maintains Quarterly Dividend for Second-Quarter 2021 at $0.39/Share; Dividend Will Not Be Reduced as a
Result of the Initiation of a Quarterly Dividend by Viatris Inc. (Viatris)(4)